BR0317857A - Tratamento de anorexia nervosa (an) e bulimia - Google Patents

Tratamento de anorexia nervosa (an) e bulimia

Info

Publication number: BR0317857A
Authority: BR; Brazil
Prior art keywords: bulimia; treatment; anorexia nervosa; anorexia; nervosa
Prior art date: 2002-09-16

Application number

BR0317857-9A

Other languages

English (en)

Portuguese (pt)

Inventor

Frederick Horro David

Agnes Ayton

Original Assignee

Amarin Neuroscience Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-09-16

Filing date

2003-09-16

Publication date

2005-12-06

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9944164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0317857(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-09-16 Application filed by Amarin Neuroscience Ltd filed Critical Amarin Neuroscience Ltd

2005-12-06 Publication of BR0317857A publication Critical patent/BR0317857A/pt

Links

208000032841 Bulimia Diseases 0.000 title abstract 3
206010006550 Bulimia nervosa Diseases 0.000 title abstract 3
208000000103 Anorexia Nervosa Diseases 0.000 title abstract 2
JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 abstract 2
208000022531 anorexia Diseases 0.000 abstract 2
206010061428 decreased appetite Diseases 0.000 abstract 2
229960005135 eicosapentaenoic acid Drugs 0.000 abstract 2
JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 abstract 2
235000020673 eicosapentaenoic acid Nutrition 0.000 abstract 2
208000035850 clinical syndrome Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Addiction (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Child & Adolescent Psychology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

BR0317857-9A 2002-09-16 2003-09-16 Tratamento de anorexia nervosa (an) e bulimia BR0317857A (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0221480.7A GB0221480D0 (en)	2002-09-16	2002-09-16	Treatment of anorexia nervosa (AN) and bulimia
PCT/GB2003/003985 WO2004024136A1 (en)	2002-09-16	2003-09-16	Eicosapentaenoic acid (epa) for treating anorexia nervosa (an) and bulimia

Publications (1)

Publication Number	Publication Date
BR0317857A true BR0317857A (pt)	2005-12-06

Family

ID=9944164

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR0317857-9A BR0317857A (pt)	2002-09-16	2003-09-16	Tratamento de anorexia nervosa (an) e bulimia

Country Status (20)

Country	Link
US (1)	US20060135608A1 (2)
EP (1)	EP1556028A1 (2)
JP (1)	JP2006503031A (2)
KR (1)	KR20050042823A (2)
CN (1)	CN1694694A (2)
AU (1)	AU2003269138A1 (2)
BR (1)	BR0317857A (2)
CA (1)	CA2499142A1 (2)
GB (1)	GB0221480D0 (2)
HR (1)	HRP20050245A2 (2)
IS (1)	IS7744A (2)
MX (1)	MXPA05002943A (2)
NO (1)	NO20051847L (2)
NZ (1)	NZ538793A (2)
PL (1)	PL375726A1 (2)
RS (1)	RS20050226A (2)
RU (1)	RU2330653C2 (2)
TW (1)	TW200410682A (2)
WO (1)	WO2004024136A1 (2)
ZA (1)	ZA200502161B (2)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2003048831A (ja)	2001-08-02	2003-02-21	Suntory Ltd	脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
WO2005046668A1 (ja) *	2003-11-14	2005-05-26	Mochida Pharmaceutical Co., Ltd.	言語障害予防・治療剤
JP4993852B2 (ja)	2004-09-17	2012-08-08	サントリーホールディングス株式会社	ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP5967855B2 (ja)	2005-06-30	2016-08-10	サントリーホールディングス株式会社	日中活動量の低下および／又はうつ症状の改善作用を有する組成物
EP2098229A4 (en)	2006-12-28	2010-03-10	Suntory Holdings Ltd	NERVE REGENERATION MEDIUM
WO2008098375A1 (en)	2007-02-15	2008-08-21	Centre De Recherche Sur Les Biotechnologies Marines	Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
US8816110B2 (en)	2007-02-15	2014-08-26	Scf Pharma Inc.	Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
CA2677670C (en)	2007-03-20	2010-08-03	Centre De Recherche Sur Les Biotechnologies Marines	Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof
US8343753B2 (en)	2007-11-01	2013-01-01	Wake Forest University School Of Medicine	Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
CN106074486A (zh) *	2009-06-15	2016-11-09	阿马里纳药物爱尔兰有限公司	在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl‑c水平的组合物和方法
CN103354839A (zh) *	2011-02-11	2013-10-16	纳幕尔杜邦公司	二十碳五烯酸浓缩物
US9447020B2 (en)	2013-10-31	2016-09-20	Scf Pharma Inc.	Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
RU2545988C1 (ru) *	2013-11-12	2015-04-10	Государственное бюджетное учреждение здравоохранения города Москвы Московский клинический научно-практический центр Департамента здравоохранения города Москвы	Способ лечения хронического запора и функциональной анорексии
WO2019153073A1 (en)	2018-02-07	2019-08-15	Scf Pharma Inc.	Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof
US20210130897A1 (en) *	2018-04-16	2021-05-06	Quadrant Biosciences Inc.	Salivary microrna levels in anorexia nervosa provide a liquid biopsy of metabolic and neuropsychiatric status
CA3054203C (en)	2018-05-03	2021-01-05	Scf Pharma Inc.	Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof
CN109276262B (zh) *	2018-07-30	2021-01-26	中国科学院心理研究所	一种用于筛选高危进食障碍的检测系统
US12226390B2 (en)	2019-07-21	2025-02-18	Scf Pharma Inc.	Cannabinoids compositions with polyunsaturated fatty acid monoglycerides, methods and uses thereof
AU2021242363A1 (en)	2020-03-27	2022-11-03	Homeostasis Therapeutics, Limited	Method of treatment for anorexia nervosa, bulimia and related clinical syndromes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9224809D0 (en) *	1992-11-26	1993-01-13	Scotia Holdings Plc	Schizophrenia
US6077828A (en) *	1996-04-25	2000-06-20	Abbott Laboratories	Method for the prevention and treatment of cachexia and anorexia
GB9901809D0 (en) *	1999-01-27	1999-03-17	Scarista Limited	Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes

2002
- 2002-09-16 GB GBGB0221480.7A patent/GB0221480D0/en not_active Ceased
2003
- 2003-09-16 TW TW092125483A patent/TW200410682A/zh unknown
- 2003-09-16 AU AU2003269138A patent/AU2003269138A1/en not_active Abandoned
- 2003-09-16 KR KR1020057004483A patent/KR20050042823A/ko not_active Withdrawn
- 2003-09-16 WO PCT/GB2003/003985 patent/WO2004024136A1/en not_active Ceased
- 2003-09-16 NZ NZ538793A patent/NZ538793A/en unknown
- 2003-09-16 BR BR0317857-9A patent/BR0317857A/pt not_active IP Right Cessation
- 2003-09-16 EP EP03750919A patent/EP1556028A1/en not_active Ceased
- 2003-09-16 RU RU2005107416/14A patent/RU2330653C2/ru not_active IP Right Cessation
- 2003-09-16 MX MXPA05002943A patent/MXPA05002943A/es not_active Application Discontinuation
- 2003-09-16 JP JP2004535695A patent/JP2006503031A/ja active Pending
- 2003-09-16 PL PL03375726A patent/PL375726A1/xx not_active Application Discontinuation
- 2003-09-16 CN CNA038251698A patent/CN1694694A/zh active Pending
- 2003-09-16 US US10/528,114 patent/US20060135608A1/en not_active Abandoned
- 2003-09-16 RS YUP-2005/0226A patent/RS20050226A/sr unknown
- 2003-09-16 HR HR20050245A patent/HRP20050245A2/hr not_active Application Discontinuation
- 2003-09-16 CA CA002499142A patent/CA2499142A1/en not_active Abandoned
2005
- 2005-03-15 ZA ZA200502161A patent/ZA200502161B/en unknown
- 2005-03-15 IS IS7744A patent/IS7744A/is unknown
- 2005-04-15 NO NO20051847A patent/NO20051847L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
WO2004024136A1 (en)	2004-03-25
JP2006503031A (ja)	2006-01-26
TW200410682A (en)	2004-07-01
RU2330653C2 (ru)	2008-08-10
KR20050042823A (ko)	2005-05-10
RU2005107416A (ru)	2006-01-20
ZA200502161B (en)	2005-09-15
PL375726A1 (en)	2005-12-12
NZ538793A (en)	2007-05-31
NO20051847L (no)	2005-04-15
US20060135608A1 (en)	2006-06-22
MXPA05002943A (es)	2005-06-03
IS7744A (is)	2005-03-15
GB0221480D0 (en)	2002-10-23
AU2003269138A1 (en)	2004-04-30
RS20050226A (sr)	2007-09-21
HRP20050245A2 (en)	2005-10-31
CN1694694A (zh)	2005-11-09
CA2499142A1 (en)	2004-03-25
EP1556028A1 (en)	2005-07-27

Legal Events

Date	Code	Title	Description
2011-10-25	B08F	Application fees: application dismissed [chapter 8.6 patent gazette]	Free format text: REFERENTE 7A. E 8A. ANUIDADE(S).
2012-05-15	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.

Publication	Publication Date	Title
BR0317857A (pt)	2005-12-06	Tratamento de anorexia nervosa (an) e bulimia
ZA200309808B (en)	2005-07-27	Compositions and methods for the diagnosis and treatment of tumor
IL159418A0 (en)	2004-06-01	Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
NL300933I2 (nl)	2018-04-26	Letermovir
BRPI0413449A (pt)	2006-10-17	compostos de quinoxalina
BRPI0417543A (pt)	2007-03-27	quinolinas úteis no tratamento de doença cardiovascular
ES2158273T3 (es)	2001-09-01	Proceso y composicion de blanqueo.
ATE432072T1 (de)	2009-06-15	Verwendung von adapalen zur behandlung dermatologischer erkrankungen
ATE350375T1 (de)	2007-01-15	17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen
DE69924375D1 (de)	2005-04-28	Verwendung von optisch reinem (+)-norcisapride für die behandlung des reizdarmsyndroms
UA83691C2 (ru)	2008-08-11	Применение замещенных 2-аминотетралинов для упреждающего лечения болезни паркинсона
EP1499328A4 (en)	2008-03-26	METHOD FOR TREATING NEKROTIZING ENTEROCOLITIS
BRPI0506449A (pt)	2006-12-26	utilização de espilantol e processo de tratamento cosmético de rugas
UY27841A1 (es)	2003-12-31	Amidas de ácidos 2-heteroarilcarboxílicos
ATE297222T1 (de)	2005-06-15	Zusammensetzungen enthaltend eine niedrige konzentration an peroxide zur behandlung von vaginitis
ATE310718T1 (de)	2005-12-15	Verfahren zur herstellung von (meth)acrylsäureanhydrid
ATE131154T1 (de)	1995-12-15	Phenylalkan(en)säuren.
CY1113871T1 (el)	2016-07-27	Διαδικασια παρασκευης γκαμπαπεντινης
SE0200844D0 (sv)	2002-03-19	Chemical compounds
DE60333205D1 (de)	2010-08-12	Histaminika zur behandlung von allergischer rhinitis
DE60220554D1 (de)	2007-07-19	Mikrowelleninduzierter prozess zur herstellung von substituierten 4-vinylphenolen
CY1107039T1 (el)	2012-09-26	Αναστολεις τριπεπτιδυλ πεπτιδασης
BRPI0408899A (pt)	2006-04-18	compostos benzo[1,2,5]tiadiazol
EA200600115A1 (ru)	2008-06-30	Производные 2-аминобензойной кислоты
DK1399142T3 (da)	2006-10-30	Anvendelse af acetyl-L-carnitin i kombination med biotin til behandlingen af patienter med type-2 insulinresistent diabetes mellitus